medigraphic.com
ISSN 1405-1710 (Print)

2012, Number 1

<< Back Next >>

Rev Cent Dermatol Pascua 2012; 21 (1)

Erythema Dischromicum Perstans

Rodríguez AMC, Ramos GA, Mejía GR

Language: Spanish
References: 22
Page: 6-11
PDF size: 94.01 Kb.


ABSTRACT

Erythema dyschromicum perstans (EDP) or ashy dermatosis (AD) is a pigmentary, asymptomatic disease of unknown etiology that appears in healthy individuals. It was first described by Oswaldo Ramirez from El Salvador in 1957. Clinical features characterized by gray o gray-blue macules, with subsequent development of erythematous borders, of slow evolution, in both genders although women are most commonly affected, occurs most frequently in dark skinned individuals, in the second decade of the life. Lesions are usually located in the face, neck, trunk, and arms, rarely in exposed areas. The differential diagnosis must be done especially with the lichen planus pigmentosus. Response to treatment is poor, although clofazimina has proved useful for treating this nosologic entity because of its cosmetic effect, and also because it induces changes in cell-mediated response.


REFERENCES

  1. Ramírez CO. Los cenicientos. Problema clínico. Memoria del Primer Congreso Centroamericano de Dermatología, San Salvador 1957: 122-130.

  2. Convit J, Kerdel-Vegas F, Rodríguez G. Erythema dyschromicum perstans. J Invest Dermatol 1961; 36: 457-462.

  3. Schwartz R. Erythema dischromicum perstans. Available in: www.emedicine.com/derm/topic132htm.2001

  4. Combemale P, Faisant M, Guennos B, Duplin M, Jean-Denis H. Erythema dyschromicom Perstans: report of a new case and critical review of the literature. J Dermatology 1998; 25: 747-753.

  5. Sardana K, Rajpal M, Garg V, Mishra D. Periorbital hyperpigmentation mimicking fixed drug eruption: a rare presentation of erythema dyschromicum perstans in a paediatric patient. JEADV 2006; 20(10): 1381-1383.

  6. Kontochristopoulos GJ, Aroni K, Anagnostopoulos G, Nakopoulou L, Tassopoulos NC. Erythema dyschromicum perstans and hepatitis C virus infection. Int J Dermatol 2001; 40(5): 346-348.

  7. Nelson MR, Lawrence AG, Staughton RC, Gazzard BG. Erythema dyschromicum perstans in an HIV antibody-positive man. Br J Dermatol 1992; 127(6): 658-659.

  8. Martínez C, Lutz EL. Perfil clínico epidemiológico de pacientes con eritema discrómico perstans (dermatitis cenicienta) en el Hospital Escuela. Revista Médica de los Postgrados de Medicina UNAH 2007; 10(1): 52-77.

  9. Naik NS. Erythema dyschromicum perstans and vitiligo. Dermatol Online J 2003; 9(4): 25.

  10. Miyagawa S, Komatsu M, Okuchi T, Shirai T, Sakamoto K. Erythema dyscromicum perstans. Inmunopathologic studies. J Am Acad Dermatol 1989; 20(5): 882-886.

  11. Piquero-Martin J, Pérez-Alfonzo R, Abrusci V, Briceño, Gross A, Mosca W, Tapia F, Convit J. Clinical trial with clofazimine for treating erythema dyschromicum perstans. Evolution of cell- mediated immunity. Int J Dermatol 1989; 28(3): 198-200.

  12. Gross A, Tapia FJ, Mosca W, Perez RM, Briceño L, Henriquez JJ, Convit J. Mononuclear cell subpopulations and infiltrating lynphocytes in erythema dyscromicum perstans and vitiligo. Histol Histopathol 1987; 2(3): 277-283.

  13. Correa MC, Memije EV, Vargas-Alarcón G, Guzmán RA, Rosetti F, Acuña-Alonzo V, Martínez-Rodríguez N, Granados J. HLA-DR association with the genetic susceptibility to develop ashy dermatosis in Mexican meztizo patients. J Am Acad Dermatol 2007; 56(4): 617-620.

  14. Homez C, Barroso J. Sobre la etiopatogenia del eritema discrómico perstans (dermatitis cenicienta). Posibilidad de una melanosis neurocutánea. Dermatología Venezolana 1995; 4(33): 149-155.

  15. Yokozeki H. Multiple linear erythema dyschromicum perstans (ashy dermatosis) in the lines of Blaschko. Dermatology 2005; 210: 356-357.

  16. Halmai O. Eritema discrómico perstans y liquen plano. Correlación clínica e inmunopatológica. Trabajo especial de investigación. Universidad Central de Venezuela, Caracas. 1992; Cap 32: 321-326.

  17. Vega ME, Waxtein L, Arenas R et al. Ashy dermatosis and lichen planus pigmentosus: a clinicopathologic study 31 cases. Int J Dermatol 1992; 31(2): 90-94.

  18. Pinkus H. Lichenoid tissue reactions. Arch Dermatol 1973; 107(6): 840-846.

  19. Bhutani LK, Bedi TR, Pandhi RK et al. Lichen planus pigmentosus. Dermatológica 1974; 149(1): 43-50.

  20. Carvajal HL, Uraga PE, Loayza VE, Sabando SR, García AI, Jeny E. Dermatitis cenicienta. Med Cutan Iber Lat Am 1986; 14: 95-99.

  21. Baranda L, Torres-Álvarez B, Cortés-Franco R, Moncada B, Portales Pérez D, González-Amaron R. Involvement of cell. Adhesion and activatión molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clozamine therapy. Arch Dermatolol 1997; 133: 325-328.

  22. Arbiser JL, Moschella SL. Clofazimina. A review of its medical uses and mechanisms of action. J Am Acad Dermatol 1995; 32: 241-247.




2020     |     www.medigraphic.com